The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
-
Patent office rejects J&J arm’s plea for HIV drug intermediate – Courtesy (Financial Express)
Pharma Live, , Intellectual Property Rights, 0
In a setback to US consumer health behemoth Johnson & Johnson, India’s patent office has rejected an application from...
-
Vanda gets favorable Markman ruling in Fanapt patent infringement litigation
Pharma Live, , Intellectual Property Rights, 0
WashingtonSaturday, September 12, 2015, 17:00 Hrs Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a favourable Markman ruling...
-
To Study The Scope & Importance Of Amended Patent Act On Indian Pharmaceutical Company With Respect To Innovation
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s2212567114002469-mainDownload
-
Wyeth denied patent for cancer drug – Courtesy ( The Financial Express)
Pharma Live, , Intellectual Property Rights, 0
Wyeth, which was acquired by US- based pharma major Pfizer Inc, has suffered a major setback in India with...
-
First Look At False Marking Under The AIA – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 14 MAY 2015POSTED IN FEDERAL CIRCUIT DECISIONSIn Sukumar v. Nautilus, Inc., the Federal Circuit took its first...
-
Evergreening, patent challenges, and effective market life in pharmaceuticals
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0167629612000057-mainDownload
-
Why orphan drug coverage reimbursement decision-makingneeds patient and public involvement
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0168851015000123-mainDownload
-
Here’s a lucrative idea: Turn a drug into an orphan med, reap 6 months extra exclusivity – Courtesy (Fierce Pharma)
Pharma Live, , Intellectual Property Rights, 0
Would-be makers of rare disease meds, rejoice: A 6-month exclusivity extension, proposed last year in Congress, has returned. The 21st...